Pearl River Capital’s Biogen BIIB Stock Holding History

Pearl River Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,605	Closed	-$1.64M	–	436
2024 Q1	$1.64M	Buy	+7,605	New	+$1.78M	0.26%	129
2023 Q4	–	Sell	-4,098	Closed	-$1.05M	–	483
2023 Q3	$1.05M	Buy	4,098 +1,376	+51%	+$368K	0.17%	209
2023 Q2	$775K	Sell	2,722 -1,378	-34%	-$410K	0.13%	246
2023 Q1	$1.14M	Sell	4,100 -6,454	-61%	-$1.79M	0.18%	176
2022 Q4	$2.92M	Buy	10,554 +1,512	+17%	+$427K	0.5%	42
2022 Q3	$2.41M	Sell	9,042 -4,954	-35%	-$1.05M	0.45%	58
2022 Q2	$2.85M	Buy	13,996 +1,422	+11%	+$291K	0.67%	31
2022 Q1	$2.65M	Buy	+12,574	New	+$2.73M	0.73%	29
2021 Q4	–	Sell	-3,714	Closed	-$1.05M	–	423
2021 Q3	$1.05M	Buy	3,714 +1,262	+51%	+$414K	0.29%	119
2021 Q2	$849K	Sell	2,452 -2,836	-54%	-$859K	0.23%	144
2021 Q1	$1.48M	Buy	+5,288	New	+$1.43M	0.47%	51
2020 Q3	–	Sell	-9,509	Closed	-$2.54M	–	359
2020 Q2	$2.54M	Buy	+9,509	New	+$2.86M	1.26%	7
2020 Q1	–	Sell	-4,449	Closed	-$1.32M	–	517
2019 Q4	$1.32M	Buy	+4,449	New	+$1.23M	0.49%	26

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pearl River Capital's BIIB Position: Q2 2024 in Review

Pearl River Capital sold out of Biogen (BIIB) in Q2 2024, closing a stake of 7,605 shares — an estimated $1.64M sold.

Pearl River Capital first reported a position in BIIB in Q4 2019 and held it in 13 quarters. The position peaked at $2.92M in Q4 2022. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Pearl River Capital reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 7,605 Biogen shares in Q2 2024, an estimated $1.64M.
Pearl River Capital first reported a position in Biogen in Q4 2019 and held it in 13 quarters.
Pearl River Capital's Biogen position peaked at $2.92M in Q4 2022.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.